Specifically, we found that PYK2 is activated in response to EGF and HRG in different breast cancer subtypes (Figure 1) and that PYK2 depletion leads to substantial inhibition of EGF/HRG-mediated cell spreading, migration and invasion (Figures 2, 3 and 5A). Here, HRG is linked to breast cancer.